CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
猪脱细胞基质水凝胶局部递送 CAR-T 细胞改善切除后胶质母细胞瘤生存
英文原题：CAR-T cells locally delivered in porcine decellularized matrix hydrogels enhance survival in post-resection glioblastoma.
查看英文原题
CAR-T cells locally delivered in porcine decellularized matrix hydrogels enhance survival in post-resection glioblastoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
被诊断为胶质母细胞瘤（GBM）的患者预后极差，生存期不足15个月，且GBM复发多为局部复发，提示局部治疗可满足患者近期和远期需求。在此，我们利用模拟患者复发的部分GBM切除小鼠模型，研究了一种基于生物材料的CAR-T 细胞局部递送方法。我们证明，将CAR-T 细胞通过水凝胶直接递送至颅内切除腔，可稳定植入针对CNS实体瘤的细胞免疫疗法，与仅接受切除术的小鼠相比，显著延长了复发GBM小鼠的生存期。
展开英文摘要原文
Patients diagnosed with glioblastoma (GBM) receive a devastating prognosis of less than 15 months, and recurrence of GBM is most often local, suggesting that regional therapies would serve both immediate and long-term needs of patients.
Here, we investigate a biomaterials-based approach for local delivery of chimeric antigen receptor (CAR) T cells using a murine model of partial GBM resection that mimics patient recurrence.
We demonstrate that hydrogel delivery of CAR T cells directly into the intracranial resection cavity can stably implant cellular immunotherapies against CNS solid tumors, and significantly prolongs survival in recurrent GBM-bearing mice compared to those receiving resection alone.
论文信息
- 作者
- Logun M、Begley SL、Hicks K、Park J、Zhang L、Binder ZA、O'Rourke DM
- 文献类型
- 预印本
- 期刊
- bioRxiv : the preprint server for biology2025 Feb 15
- 原文标识
- PubMed 39990473 · DOI 10.1101/2025.02.11.637648